CliffBio
small molecule

NAMZARIC

DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE

Loss of exclusivityDecember 2029latest FDA-listed patent expiry
CompanyAbbVie Inc. →View the full company profile on CliffBio

Drug detail

Brand nameNAMZARIC
Active ingredientDONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE
Strength10MG;28MG
Dosage formCAPSULE, EXTENDED RELEASE
RouteORAL
ModalitySmall molecule
FDA approvalDecember 2014
Marketing statusRX

Listed patents

PatentExpiresType
8058291December 2029use U-1641
8039009*PEDSeptember 2029—
8039009March 2029use U-1641

More from AbbVie Inc.

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

NAMZARIC patent cliff — loss of exclusivity December 2029 | CliffBio